MedTrace Logo

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

NCT06499350 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-03-10

No results posted yet for this study

Summary

The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

FC084CSA+Tislelizumab combination (dose escalation)

Increasing dose levels of FC084CSA+fixed dose Tislelizumab combination therapy

DRUG

RP2D of FC084CSA+Tislelizumab combination (dose expansion)

RP2D of FC084CSA+fixed dose Tislelizumab combination therapy

Sponsors & Collaborators

  • FindCure Biosciences (ZhongShan) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Caicun Zhou · Shanghai East Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-13
Primary Completion
2026-07-01
Completion
2026-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06499350 on ClinicalTrials.gov